Korean Botox

What Is Korean Botox? Mechanism, Clostridium Botulinum & Safety Evidence

Korean Botox is an umbrella term for Korean botulinum toxin type A products manufactured in South Korea and used in aesthetic medicine and clinical protocol discussions. Derived from Clostridium botulinum neurotoxin, these products act at the neuromuscular junction by inhibiting acetylcholine release, resulting in temporary relaxation of targeted facial muscles. The growing interest in Korean Botox reflects the expansion of GMP-manufactured injectable neurotoxins, broader regulatory approvals, and Korean innovation in both liquid and lyophilized toxin formulations.

While these brands share the same core mechanism, they vary by bacterial strain, excipients, formulation type, vial size, and local regulatory status. Major products, including LETYBO™, NABOTA®, Jeuveau®, and INNOTOX®, possess product-specific clinical data. In professional practice, they are considered safe, cost-effective alternatives to Western neurotoxins when properly stored, dosed correctly, and administered by qualified personnel.

In aesthetic medicine, they are primarily used to treat dynamic expression lines caused by repeated muscle movement, such as forehead lines, glabellar frown lines, and crow’s feet. Clinical outcomes depend heavily on product selection, patient anatomy, precise dilution, and brand-specific dosing guidance.

Korean Botox Brands: Clinical Profiles, Manufacturers & Formulation Types

The Korean Botox brand landscape is best organized by manufacturer. While these products are often grouped under a single category, they differ significantly in formulation, preparation, and jurisdiction-specific approval status, meaning they should not be treated as interchangeable.

Hugel: LETYBO™ and BOTULAX®

• LETYBO™: A lyophilized toxin approved in the United States under the nonproprietary name letibotulinumtoxinA-wlbg. As of mid-2026, LETYBO™ holds US FDA approval (granted February 2024) for the temporary improvement of moderate-to-severe glabellar lines in adults.
• BOTULAX®: A widely exported lyophilized product available in 100-unit and 200-unit configurations. Backed by Hugel’s three Phase 3 BLESS trials, which enrolled over 1,000 participants globally, BOTULAX® also features published RCT evidence demonstrating non-inferiority to onabotulinumtoxinA across therapeutic indications, including pediatric cerebral palsy spasticity.

Medytox: INNOTOX® and MEDITOXIN®

• INNOTOX®: A clinically distinct, ready-to-use liquid formulation requiring no reconstitution. This eliminates dilution variability and supports rapid, standardized clinic workflows. INNOTOX®’s underlying liquid technology (MT10109L) demonstrated comparable safety and efficacy to onabotulinumtoxinA for glabellar lines in a 168-subject Phase 3 trial. Its North American liquid analog, nivobotulinumtoxinA, confirmed similar success across two randomized, placebo-controlled trials.
• MEDITOXIN®: A traditional lyophilized formulation with a long-standing presence in South Korea. MEDITOXIN® is available in flexible 100-unit, 150-unit, and 200-unit vial layouts to suit varying clinic volumes.

Daewoong: NABOTA® and Jeuveau®

Daewoong manufactures NABOTA®, a lyophilized toxin marketed in the United States as Jeuveau® (prabotulinumtoxinA-xvfs). It carries US FDA approval (granted February 2019) for adult glabellar lines. In Western Phase 3 trials, prabotulinumtoxinA achieved a statistically higher responder rate than onabotulinumtoxinA at day 30 (87.2% vs. 82.8%) with a class-consistent safety profile, making it a primary choice for practices requiring strict Western regulatory recognition.

Other Korean Botulinum Toxin: LIZTOX®, Re N Tox®

• LIZTOX®: A lyophilized product typically packaged in 100-unit vials.
• Re N Tox®: A lyophilized alternative frequently discussed in wholesale channels. As of mid-2026, neither Re N Tox® nor LIZTOX® is confirmed as FDA-approved in the United States, though they maintain registration in various international markets.

Botox Units Explained: Dosing Decisions & Treatment Area Reference

Most Korean botulinum toxins are commonly available in 100-unit vials. Higher-volume presentations, including 200-unit options, may be available for products such as BOTULAX® and MEDITOXIN®, depending on the market. These larger vial sizes may support workflow planning in higher-volume clinics, but vial size should never determine treatment dose. Dosing decisions should remain based on the specific product, indication, muscle target, dilution, patient anatomy, and practitioner assessment.

Common Korean Botox treatment areas include:

• Glabellar lines: Often treated by targeting the corrugator and procerus muscles responsible for frown lines and lines between the eyebrows.
• Forehead lines: Typically associated with frontalis activity and require careful dosing to preserve natural brow position.
• Lateral canthal lines: Commonly called crow’s feet, addressed by targeting orbicularis oculi activity.
• Perioral lines: May be considered in selected cases where fine dynamic lines around the mouth are related to muscle movement.
• Masseter applications: Used in some aesthetic and functional protocols where masseter activity, facial contour, or muscle prominence is being assessed.
• Lines between the eyebrows: Often grouped with glabellar treatment planning, but still requiring precise muscle mapping and brand-specific dosing review.

Treatment planning should account for the target facial muscles, approved indication, patient anatomy, prior toxin exposure, desired degree of correction, and the condition of the treatment area. For practitioners reviewing how long Korean Botox lasts, effects are commonly discussed in the three- to six-month range. Duration varies by brand, dose, dilution, metabolism, muscle activity, injection technique, and patient-specific response.

Reconstitution of Korean Botox & Storage Temperature

Botulinum toxin units are product-specific potency measurements and are not interchangeable across brands. A unit assigned to a Korean neurotoxin reflects that specific manufacturer’s assay system and labeling. That said, practitioners should not apply a universal unit conversion between Korean and Western brands. While 100-unit formats are standard, certain brands offer 150-unit or 200-unit configurations to support high-volume clinic workflows, though vial size should never dictate the patient’s dose.

Reconstitution Protocol

Lyophilized formulations (LETYBO™, BOTULAX®, NABOTA®, MEDITOXIN®, Re N Tox®, and LIZTOX®) require reconstitution with sterile normal saline, where the selected saline volume determines the final concentration. INNOTOX® remains the primary exception to this protocol. As a ready-to-use liquid toxin, it requires no physical reconstitution, effectively eliminating dilution variability at the point of care.

Storage Temperature

Storage requirements must be verified on the specific manufacturer’s label. Most brands mandate refrigerated handling within a strict 2–8°C range, though stability windows can change significantly before and after reconstitution. Sourcing and clinical teams must thoroughly document cold-chain integrity, lot-number traceability, and expiration dates for both liquid and lyophilized formats.

Is Korean Botox FDA-approved? Legal Status & Jurisdiction Guide

As of mid 2026, LETYBO™ and NABOTA®/Jeuveau® are the clearest examples of FDA-approved Korean botulinum toxin products in the US, with approval limited to specific aesthetic indications in adults. Other products, including INNOTOX®, BOTULAX®, MEDITOXIN®, Re N Tox®, and LIZTOX®, are not confirmed as FDA-approved in the United States, although some may be approved or registered in South Korea or other markets. Wholesale buyers and clinical procurement teams should verify manufacturer documentation, approval status, storage records, expiry dates, certificates of analysis where applicable, and lot-number traceability before sourcing, stocking, or administering any Korean Botox brand.

Comparing Korean Botox Brands: Best Korean Botulinum Toxin for Your Practice

There is no single best Korean botulinum toxin for every practice. Brand selection depends on indication, patient profile, practitioner workflow, and procurement considerations, and the most useful comparison is not a ranking, but a clear look at what each product does well.

INNOTOX® vs NABOTA®

INNOTOX® is the first commercially available liquid formulation of botulinum toxin that requires no reconstitution. That means no dilution variability, immediate preparation readiness, and consistent concentration at the point of injection, which is an advantage in high-volume settings or where standardization across practitioners matters.

Medytox manufactures INNOTOX®, and its liquid formulation technology has been evaluated in peer-reviewed literature:

• A double-masked, randomized, phase 3 study comparing liquid-type botulinum toxin type A (MT10109L) versus onabotulinumtoxinA in 168 subjects found comparable efficacy and safety for moderate-to-severe glabellar lines, with the added benefit of no reconstitution required.
• A subsequent phase 3 program for nivobotulinumtoxinA, the North American liquid-type analog from Medytox, confirmed efficacy and safety in treating glabellar and lateral canthal lines in two randomized, placebo-controlled trials.

NABOTA® is approved in the US market as Jeuveau® (prabotulinumtoxinA-xvfs), offering distinct clinical advantages: lyophilized vial stability, FDA approval (granted February 2019), and a published Western RCT dataset.

• In phase 3 trials, prabotulinumtoxinA achieved a higher responder rate than onabotulinumtoxinA at day 30 (87.2% vs 82.8%) for moderate-to-severe glabellar lines, with a tolerability profile consistent with the botulinum toxin class.

For practitioners who prioritize regulatory standing or whose procurement environment requires it, that approval status is a meaningful differentiator. These two products suit different clinical and procurement scenarios; neither is universally preferable.

BOTULAX® vs MEDITOXIN®

BOTULAX® is manufactured by Hugel, the same company behind FDA-approved LETYBO™ (letibotulinumtoxinA-wlbg, approved February 2024), and is supported by that manufacturer’s three phase 3 BLESS trials enrolling over 1,000 participants in the US and Europe. BOTULAX® is widely exported, available in 100- and 200-unit vials, and has published RCT evidence in therapeutic indications: a randomized controlled trial in children with spastic cerebral palsy demonstrated non-inferiority of letibotulinumtoxinA versus onabotulinumtoxinA on the Physician’s Rating Scale at 12 weeks.

MEDITOXIN® comes from Medytox, also the manufacturer of INNOTOX®, and has a long-standing clinical presence in South Korea. It is available in 100-, 150-, and 200-unit configurations depending on the market, offering flexibility for practices with varying treatment volume. Both BOTULAX® and MEDITOXIN® are lyophilized. No head-to-head RCT has directly compared the two, so neither should be ranked above the other; each should be evaluated on its own profile relative to the clinical context.

Where Can Practitioners Buy Korean Botox Online?

Access to Korean Botox should be limited to licensed or otherwise qualified professionals, including aesthetic medicine physicians, dermatologists, plastic surgeons, and registered aesthetic practices operating within local regulatory requirements. Practitioners evaluating where to buy Korean Botox online or source it through wholesale channels should verify the exact brand, manufacturer, formulation, regulatory status, product authenticity, lot-number traceability, storage records, packaging integrity, expiry date, and certificate of analysis or equivalent manufacturer documentation where applicable. When buying online, compliance and handling requirements should be confirmed before practitioners check for wholesale buying options.

Practitioners looking to buy botulinum toxins can contact Doctor Medica’s staff for guidance on supplier documentation and sourcing requirements.

FAQs

1. What is the mechanism of action of Korean Botox?

Korean Botox products are botulinum toxin type A products derived from Clostridium botulinum. They block acetylcholine release at the neuromuscular junction by interfering with SNARE-mediated neurotransmitter release, producing temporary relaxation of targeted facial muscles. The mechanism is pharmacologically comparable to Western botulinum toxin products, although brands differ in formulation, unit potency, and regulatory status.

2. Is Korean Botox clinically validated — what does the evidence say?

Several major Korean brands have clinical evidence supporting use in aesthetic indications. LETYBO™, NABOTA®/Jeuveau®, and INNOTOX® have published or regulatory data, while BOTULAX® and MEDITOXIN® also have market-specific clinical use histories. Evidence should be evaluated by product, indication, dose, population, and jurisdiction rather than generalized across all Korean brands.

3. How do Korean Botox units compare to Western brands?

Botulinum toxin units are not interchangeable across brands because unit potency depends on the product’s assay and formulation. Practitioners should not convert units directly between Korean and Western products without brand-specific clinical guidance. A 100-unit vial from one brand should not be assumed to be equivalent in dosing behavior to another brand’s vial.

4. What is the reconstitution protocol for Korean Botox?

Lyophilized Korean products such as BOTULAX®, NABOTA®, MEDITOXIN®, Re N Tox®, and LIZTOX® require reconstitution with sterile normal saline according to brand-specific labeling. INNOTOX® is the main exception because it is a liquid formulation and does not require reconstitution. Storage and post-reconstitution use windows should be verified against the current label.

5. Which Korean Botox brands are FDA-approved?

As of mid 2026, LETYBO™ and NABOTA®/Jeuveau® are FDA-approved Korean botulinum toxin products for specific aesthetic indications in adults. Other brands such as INNOTOX®, BOTULAX®, MEDITOXIN®, Re N Tox®, and LIZTOX® are not confirmed as FDA-approved in the United States. Practitioners should verify the current FDA status before procurement or use. Medical professionals looking to order Korean botox online must provide a valid license.

6. What is the clinical differentiator for INNOTOX® vs NABOTA®?

INNOTOX® is differentiated by its liquid, ready-to-use formulation, which avoids reconstitution and may reduce dilution variability. NABOTA®/Jeuveau® is differentiated by US FDA approval, lyophilized vial format, and published Western clinical trial data. Both are botulinum toxin type A products, but they fit different workflows and regulatory priorities.

7. How long do Korean Botox results last across different brands?

Effects lasting three to six months are commonly discussed across botulinum toxin type A products. Duration varies by brand, dose, treatment area, dilution, patient metabolism, muscle activity, and injection technique. There is no single duration that applies equally to every Korean brand. Practitioners should rely on brand-specific data and patient follow-up.

References

1. Liu S, Cong L, Pongprutthipan M, et al. Use of LetibotulinumtoxinA for Aesthetic Treatment of Asians: A Consensus. Aesthet Surg J. 2023;43(11):NP962-NP974. doi:10.1093/asj/sjad151
2. Dressler D, Kim N, Johnson EA, Adib Saberi F. Korean botulinum toxins. J Neural Transm (Vienna). Published online January 31, 2026. doi:10.1007/s00702-025-03076-x
3. Frevert J, Ahn KY, Park MY, Sunga O. Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018;11:327-331. Published 2018 Jul 5. doi:10.2147/CCID.S160723
4. Hong SO. Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques. Toxins (Basel). 2023;15(2):82. Published 2023 Jan 17. doi:10.3390/toxins15020082

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.